Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

Jung Lee, Hyun; Gulati, Roman; Sayar, Erolcan; A. Patel, Radhika; Itagi, Pushpa; M. Richards, Helen; Persse, Thomas; Arora, Sonali; Coleman, Ilsa; Adil, Mohamed; L. Schuster, Samantha; Shokri, Farinaz; L. Wright, Jonathan; Y. Yu, Evan; D. True, Lawrence; Chambers, Meagan; E. Hawley, Jessica; H. Cheng, Heather; T. Schweizer, Michael; Grivas, Petros; S. Nelson, Peter; Bruce Montgomery, R.; C. Hsieh, Andrew; Vakar-Lopez, Funda; Morrissey, Colm; Lam, Hung-Ming; Ha, Gavin; S. Tretiakova, Maria; C. Haffner, Michael; Raychaudhuri, Ruben

doi:10.1158/2767-9764.crc-25-0069

Public

Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

Shared by NobleBlocks on Aug 1, 2025 • 12:00 AM UTC

Authors:

Hyun Jung Lee

Roman Gulati

Erolcan Sayar

Abstract

Abstract HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the landscape of HER2 expression in advanced prostate cancer...

Discussions